A phase II single-arm open-label multi-center study of sirolimus in previously treated idiopathic multicentric Castleman disease

Recruiting
18 years - 80 years
All
Phase 2
20 participants needed
1 Location

Brief description of study

The purpose of this study is to determine the effects of sirolimus in patients (males or females aged 18-80) with idiopathic multicentric Castleman Disease (iMCD) who are either unable to tolerate siltuximab or tocilizumab, or have failed, relapsed, or are refractory to this treatment. Subjects will take sirolimus daily for 12 months. During this time, the study team will collect data from tests and procedures done as per standard of care. In addition, they will collect research samples.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: castleman,castlemans,iMCD,MCD
  • Age: 18 years - 80 years
  • Gender: All
Updated on 19 Feb 2024. Study ID: 832465

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.